drugset / Trial / NCT00192712

Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer

NCT00192712

Phase 2/3 Completed 20 enrolled Rambam Health Care Campus
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.

Timeline

Start
2002-11
Primary completion
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule
Subject Irinotecan Small molecule